SCHEMBL6092967

SCHEMBL6092967

Cc1cc(C)c(-c2cccn3c2cc2nc(C)nc(Cl)c23)c(C)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.35
LCK P06239 2/20 0.33
MAT2A P31153 1/20 0.33
PTPN2 P17706 1/20 0.33
ALDH1A1 P00352 3/20 0.32
GLA P06280 3/20 0.32
GAA P10253 3/20 0.32
HPGD P15428 3/20 0.32
KDM4E B2RXH2 3/20 0.32
HTT P42858 1/20 0.32
POLB P06746 2/20 0.31
MAPT P10636 2/20 0.31
HTR3E A5X5Y0 2/20 0.31
HTR3B O95264 2/20 0.31
HTR3A P46098 2/20 0.31
HTR3D Q70Z44 2/20 0.31
HTR3C Q8WXA8 2/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6093564 0.85 CDK5 (0.32) PTPN1PTPN2MAPTHTR3EHTR3B
SCHEMBL6092887 0.82 PTPN1 (0.37) PTPN1LCKMAT2APTPN2ALDH1A1
SCHEMBL6093905 0.78 NPY1R (0.35) ALDH1A1
SCHEMBL6095943 0.78 LMNA (0.36) PTPN1PTPN2ALDH1A1GLAGAA
SCHEMBL7004989 0.74 GAA (0.33) PTPN1LCKPTPN2ALDH1A1GLA
SCHEMBL6095564 0.72 NPY1R (0.42) ALDH1A1MAPTKMT2ALMNATP53
SCHEMBL6094470 0.72 CRHR1 (0.33) ALDH1A1GLAGAAKDM4ELMNA
SCHEMBL6093439 0.71 NPY1R (0.40)
SCHEMBL5787033 0.65 CRHR1 (0.36) KDM4EHTT
SCHEMBL7004385 0.63 MAPT (0.37) PTPN1LCKMAT2AALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074929-B2 Certain alkylene diamine-substituted heterocycles NEUROGEN CORP. (US) 2006-07-11 US disclosed
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2004-11-18 US disclosed
US-6696445-B2 NEUROPEPTIDE Y RECEPTOR ANTAGONISTS COMPRISING HETEROCYCLIC NITROGEN COMPOUNDS AND/OR PRODRUGS USED FOR PROPHYLAXIS OF EATING AND CARDIOVASCULAR DISORDERS NEUROGEN CORPORATION 2004-02-24 US disclosed
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2003-08-21 US disclosed
US-6506762-B1 Mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. Novel compounds are for eating NEUROGEN CORPORATION 2003-01-14 US disclosed
EP-1224187-A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES NEUROGEN CORPORATION (US) 2002-07-24 EP disclosed
WO-2001023389-A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES NEUROGEN CORPORATION (US) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R PTPN1 489/4885LCK 1128/4885MAT2A 3449/4885
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R PTPN1 481/4885LCK 1175/4885MAT2A 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.